Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 6 , ISSUE 2 ( July-December, 2016 ) > List of Articles

MINI REVIEW

Cost Assessment of Hepatitis B Virus-related Hepatitis in Bangladesh

Muntasir Chaudhury, Mohammad H Uddin, Sheikh M Noor-E Alam, Mohammad A Rahim

Citation Information : Chaudhury M, H Uddin M, M Noor-E Alam S, A Rahim M. Cost Assessment of Hepatitis B Virus-related Hepatitis in Bangladesh. Euroasian J Hepatogastroenterol 2016; 6 (2):163-166.

DOI: 10.5005/jp-journals-10018-1190

License: CC BY-NC 4.0

Published Online: 01-07-2016


Abstract

Hepatitis B virus (HBV) infection is endemic in Bangladesh. Studies have indicated that HBV is the major cause of chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC) in this country. Recently, HBV-related acute on chronic liver failure (HBV-ACLF) has emerged as a serious and emergent medical problem in Bangladesh. To develop a strategy to address HBV-related problems and their influence on health care delivery system, proper understandings about extent of problems and nature of economic burden should be explored. Conservative estimates indicate that about 50 million or more of Bangladeshi have been infected by HBV at some point of their life. Out of the total Bangladeshi population, about 2 to 5% is chronically infected with HBV (about 3–8 million) (1–6%) and considerable number of these patients will eventually develop LC, HCC, or ACLF (about 1 million). Although proper statistics is lacking, it is estimated that HBV-related liver diseases account for a majority of hospital admissions and around 20,000 deaths every year in Bangladesh. In addition, complex clinical features of HBV-related liver diseases have been documented in Bangladesh that show similarity and differences from HBV infection in other Asian countries. Although vaccination against HBV and containment of horizontal transmission are in progress in Bangladesh for reduction of new HBV infection, there is a lack of national strategy for treatment of millions of chronic HBV-infected subjects. This paper will provide an insight regarding the economic impact of HBV in Bangladesh that may act as a primary impetus for developing national HBV eradication program, a goal set by World Health Organization (WHO).


PDF Share
  1. Shirin T, Ahmed T, Iqbal A, Islam M, Islam MN. Prevalence and risk factors of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections among drug addicts in Bangladesh. J Health Popul Nutr 2000 Dec;18(3): 145-150
  2. Chronic carriers of hepatitis B virus in Bangladesh: a comparative analysis of HBVDNA, HBeAg/anti-HBe, and liver function tests. Southeast Asian J Trop Med Public Health 2002 Mar;33(1):110-117
  3. Seroepidemiology of hepatitis B and delta virus infections in Bangladesh. J Trop Pediatr 2003 Dec;49(6):371-374
  4. Epidemiology of hepatitis B virus in Bangladeshi general population. Hepatobiliary Pancreat Dis Int 2008 Dec;7(6):595-600
  5. Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, Bangladesh. BMC Infect Dis 2010 Jul 15;10:208
  6. Prevalence of genotypes and subtypes of hepatitis B viruses in Bangladeshi population. SpringerPlus 2016 Mar 5;5:278
  7. Anti-HBc screening of blood donors in Bangladesh: relevance to containment of HBV propagation. J Clin Exp Hepatol 2016 Jun;6(2):115-118
  8. Profile of HBeAg negative chronic HBV infection in Bangladesh. Bangladesh J Hepatol 2015;2(1):9-12
  9. Early termination of immune tolerance state of hepatitis B virus infection explains liver damage. World J Hepatol 2014 Aug 27;6(8):621-625
  10. Hepatitis B surface antigen- negative, but HBV DNA-positive subjects in Bangladesh: clinical and public health importance of occult HBV infection in developing countries. Bangladesh Med Res Counc Bull 2012;38(3):104-107
  11. Biochemical, virological, immunological and histopathological features of 702 incidentally detected chronic hepatitis B virus carriers in Bangladesh. Digestion 2012;86(1):1-5
  12. Assessment of clinical utility of low and high normal alanine aminotransferase values in patients with chronic hepatitis B virus infection at Bangladesh. Digestion 2011;83(1-2):60-64
  13. Clinical use of liver biopsy for the diagnosis and management of inactive and asymptomatic hepatitis B virus carriers in Bangladesh. J Med Virol 2010 Aug;82(8):1350-1354
  14. Direct economic burden and influencing factors in patients with hepatitis B virus related diseases in Jiangsu, China. Asia Pac J Public Health 2015 Mar;27(Suppl 2):41S-48S
  15. Economic burden of hepatitis B virusrelated diseases: evidence from Iran. Hepat Mon 2015 Apr 25;15(4):e25854
  16. Financial burden on the families of patients with hepatitis B virus-related liver diseases and the role of public health insurance in Yunnan province of China. Public Health 2016 Jan;130:13-20. Mamun Al Mahtab et al 166 17. Nayagam S, Conteh L, Sicuri E, Shimakawa Y, Suso P, Tamba S, Njie R, Njai H, Lemoine M, Hallett TB, et al. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. Lancet Glob Health 2016 Aug;4(8):e568-e578
  17. The societal burden of chronic liver diseases: results from the COME study. BMJ Open Gastroenterol 2015 Mar 30;2(1):e000025.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.